Title |
Autologous Immune Enhancement Therapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
|
---|---|
Published in |
Indian Journal of Hematology and Blood Transfusion, February 2014
|
DOI | 10.1007/s12288-013-0327-3 |
Pubmed ID | |
Authors |
Revathi Raj, M. Deenadayalan, G. Vimal Kumar, Vipin Khandelwal, Karuna Sri, Rajappa Senthilkumar, Samuel J. K. Abraham, Terunuma Hiroshi |
Abstract |
Advances in current treatment regimens in childhood acute lymphoblastic leukemia (ALL) have resulted in cure rates of 75-80 %. Some molecular genetic abnormalities confer a poor prognosis. Of these, the chromosomal translocation t (9;22)-Philadelphia chromosome is associated with the worst outcome in childhood ALL. Optimal therapy for this variant of ALL includes chemotherapy as per high risk schedule, imatinib and early stem cell transplantation. We report here the successful natural killer cell-based autologous immune enhancement therapy along with chemotherapy and imatinib in a patient with Philadelphia chromosome positive ALL. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
India | 1 | 33% |
Unknown | 2 | 67% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 67% |
Scientists | 1 | 33% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 6 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 2 | 33% |
Student > Master | 2 | 33% |
Other | 1 | 17% |
Unknown | 1 | 17% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 3 | 50% |
Immunology and Microbiology | 1 | 17% |
Psychology | 1 | 17% |
Unknown | 1 | 17% |